China spent $1.03 trillion on research and development in 2024, edging past the United States' $1.01 trillion investment and ending two decades of American dominance at the top of the global R&D table. The OECD's Main Science and Technology Indicators, the international standard for cross-country comparison, recorded the crossover in the most recent year of compiled data.

What does the OECD comparison actually show?

The headline numbers arrive in current dollars. The OECD's own chart expresses the same totals in purchasing-power-parity (PPP) terms, a conversion designed so that one dollar buys equivalent goods and services in each country. The PPP framing has shown China's rise for several years; the 2024 data simply close the gap at face value.

China's growth trajectory made the crossover almost inevitable. Since 2004, Chinese R&D expenditure has climbed at more than 14% per year, more than double the U.S. rate over the same period. Five-year plans have repeatedly elevated science and technology, embedding R&D as a measurable policy target.

Where does spending land on R&D intensity?

R&D intensity, the ratio of R&D outlay to gross domestic product, has reached 2.7% in China. That figure places it among advanced OECD economies on this measure. The United States, Germany, Japan, and South Korea still lead the intensity ranking. China has therefore caught up by share of economy while still trailing by depth.

How is the money translating into research output?

Chinese institutions now occupy the top of the Nature Index ranking for scientific publications in the physical sciences. Researchers in China also lead the world in artificial intelligence publication counts, a gap documented in Science magazine's 2024 database analysis.

Several flagship instruments illustrate where the dollars go:

• Fusion: The Experimental Advanced Superconducting Tokamak (EAST) in Hefei has repeatedly set records for long-duration plasma sustainment.
• Quantum: A prototype quantum communications network links Beijing and Shanghai, and now extends to South Africa via satellite.
• Magnets and light sources: Chinese labs have built record-setting resistive magnets and one of the world's largest synchrotrons, both workhorses for chemistry, materials, and structural biology.

These capabilities shift the practical question for R&D managers abroad. Chinese capacity now affects where to source hard-to-build components, where to place joint calls, and which fields of basic research face stronger competition for first-mover position.

What does the timing mean for Washington?

The OECD release lands one week before the White House's planned FY27 budget delivery, scheduled for April 3. Multiple reports indicate the request will propose a 20% cut to National Institutes of Health funding, on top of the steep science reductions in the FY26 request. Congress restored most of the FY26 cuts. Whether the new OECD data point motivates a similar outcome for science in FY27 remains the open question, according to Matt Hourihan, associate vice president for government relations and public policy at AAU, who authored the analysis.

That framing matters because total U.S. R&D sums federal outlays, business expenditure, and other sources. A federal share cut in FY27 would not, by itself, close the 2024 gap of roughly $20 billion. It would, however, reduce one of the inputs that historically fueled U.S. leadership in basic research, with downstream effects on graduate training, shared instrumentation, and the early-stage pipeline that companies later commercialize.

What should R&D leaders watch next?

Two data points will sharpen the picture by late 2026. The first is the OECD's 2025 update, which will indicate whether China's lead widens or plateaus after the headline crossover. The second is the FY27 appropriations cycle, where congressional markups will reveal whether the new gap translates into restored federal science budgets. R&D managers planning multi-year programs, particularly those dependent on U.S. shared facilities or on first-author publication races, now have a concrete macro signal that the long-assumed American spending lead is no longer a safe assumption.